RonaldGNahassMDMHCM,FIDSA

Infectious Disease • Hillsborough, NJ

HIV/AIDS Medicine, Healthcare Associated Infections, Mycobacterial Disease

President-ID CARE, Clinical Professor of Medicine, Rutgers-RW Johnson Medical School

Join to view full profile

Dr. Nahass is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nahass' full profile

Already have an account?

Office
105 Raider Blvd
Suite 101
Hillsborough, NJ 08844
Phone+1 908-281-0221

Fax+1 908-281-0890

Summary

Ronald G. Nahass, MD, FACP, FIDSA, was born and raised in New Jersey. After graduating cum laude from Rensselaer Polytechnic Institute in 1979, he earned his medical degree at the University of Medicine and Dentistry of New Jersey – The Robert Wood Johnson Medical School (RWJMS) in 1982. He completed an internal medicine residency at the Robert Wood Johnson University Hospital (RWJUH) in 1985 and was selected Chief Medical Resident the following year. Dr. Nahass was board certified in Internal Medicine in 1985 and Infectious Diseases in 1988. He received special certification by the American Academy of HIV medicine as an HIV specialist in 2004. He completed the Advanced Special Certification in Hepatitis B in 2006. Dr. Nahass was named the winner of Princeton HealthCare System's 2008 Distinguished Physician Humanitarian Award for his work with patients with AIDS over the last 20 years.

Dr. Nahass is a Fellow of the American College of Physicians, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America. Dr. Nahass is Chairman of the Quality Committee of the Infectious Diseases Society of America.

He has been and active member of the Infectious Diseases Society of America having served on the Clinical Affairs Committee, the Value Subcommittee and is currently Chairman of the Quality Committee. He has also earned a master’s degree in Healthcare Management from Harvard University.

He is a frequent lecturer on HIV, hepatitis, healthcare reform and value of infectious diseases medicine. He is a reviewer for the Archives of Internal Medicine, Clinical Infectious Diseases, and the American Journal of Infection Control. He has published extensively, presented at numerous national meetings and has extensive clinical research experience in viral disease like HIV, HCV, HBV and Herpes as well as infection prevention and patient safety.

Education & Training

Harvard School of Public HealthMHCM, Healthcare Leadership, 2010 - 2012
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1982 - 1986
Rutgers Robert Wood Johnson Medical SchoolClass of 1982
Rensselaer Polytechnic InstituteB.S., Cum Laude, 1979

Certifications & Licensure

FL State Medical License 2020 - Present
NJ State Medical License 1983 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly
.Special commendation for self directed learning American Medical Association
Distguished Attending Robert Wood Johnson University Hospital
New York Magazine: Top Doctors Castle Connolly, 2010-2016
America's Top Doctors Castle Connolly, 2002-2016
Physicians Recognition Award with Special Commendation AMA, 2015
Legend In Medicine Award Smith Foundation for Infectious Diseases, 2015
Top 1% Physician In US Recognition US News and World Report, 2014
Medical Guide to Best Doctors Northeast region and National Best Doctor in America Castle, Connolly, 2014
Inside Jersey Magazine Top Doctors Castle Connolly, 2009-2014
CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Top Doctor Recognition New York Magazine, 2010
NJ.com Top Doctors Castle Connolly, 2009
Physician Humanitarian award University Medical Center, 2008
New Jersey Life: Top Doctors Castle Connolly, 2005
New Jersey Monthly: Top Doctors Castle Connolly, 2003
Top Infectious Diseases Physician Award New Jersey Monthly Magazine, 1996, 2001
Volunteer Faculty Award Robert Wood Johnson Medical School, 1993, 1998, 2000-2001, 2010
Recognition of Participation - Active Teacher in Family Practice American Academy of Family Physicians, 1991
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

A Study of the Long-Term Outcomes of HIV-Positive Patients Start of enrollment: 1999 Mar 01
Completed
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs Start of enrollment: 1999 Sep 01
Completed
Phase 2
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Start of enrollment: 2000 Mar 01
Completed
Phase 3
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals Start of enrollment: 2002 Apr 01
Completed
Phase 2
Collection of Blood Samples From HIV Infected People Start of enrollment: 2005 Jan 01
Completed
Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants Start of enrollment: 2002 Jan 01
Completed
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir Start of enrollment: 2008 Jul 01
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2010 Mar 01
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2010 Apr 01
Completed
Phase 3
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus Start of enrollment: 2011 Jun 01
Completed
Phase 2
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment Start of enrollment: 2011 May 01
Completed
Phase 3
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon Start of enrollment: 2012 Mar 01
Completed
Phase 3
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Start of enrollment: 2012 Dec 26
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Start of enrollment: 2013 Mar 12
Completed
Phase 3
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Start of enrollment: 2013 Mar 27
Completed
Phase 3
PATH For Triples Study: Medication and Lifestyle Adherence for HIV+ Patients Start of enrollment: 2014 Feb 01
Completed
Not Applicable
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection Start of enrollment: 2015 Feb 17
Completed
Phase 2
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection Start of enrollment: 2015 Feb 16
Completed
Phase 2
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Start of enrollment: 2016 Sep 14
Completed
Phase 2
Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Start of enrollment: 2018 Jan 15
Unknown status
Phase 4
Join now to see all

Publications & Presentations

PubMed

145 citations
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
Paul Y. Kwo, Norman Gitlin, Ronald Nahass, David E. Bernstein, K.P. Etzkorn
Hepatology. 2016-08-01
171 citations
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M. Jacobson, Eric Lawitz, Edward Gane, Bernard Willems, Peter Ruane
Gastroenterology. 2017-07-01
1052 citations
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson, Eric Lawitz, Stuart C. Gordon
The New England Journal of Medicine. 2014-04-16

Journal Articles

Linkage to Care for Hepatitis C Virus (HCV) Among Suburban Heroin Users in New Jersey
Akyar E, Seneca KH, Akyar S, Schoefield N, Schwartz MP, Nahass RG, Emerg Infect Dis, 1/1/2016
Thorn-Induced Alternaria septic arthritis and osteomyelitis of the hand
Li Boning, Boretz R, Nahass RG, Infect Dis Clin Practice, 1/1/2016
PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes wit...
Foster GR, Pianko C, Cooper,A Brown A,Forton D, Nahass RG, Sofosbuvir, Hepatology, 1/1/2015
Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes
Brown RS, Puoti M, Cooper C, Wyles DL, Sepe TE, Nahass RG, et al, Journal of Hepatology, 1/1/2015
The infectious diseases physician in the future of healthcare;not only about antibiotic prescribing
Nahass RG, CID, 1/1/2015
The next frontier in hospital/physician co-management
Nahass RG, Phys Leadership J, 1/1/2015
Infectious diseases manpower; a looming crisis
Nahass RG, Infect Dis Clin Practice, 1/1/2015
Clinical and economic impact of empiric extended infusion piperacillin-tazobactam in a community medical center
Brunetti L, Poustchi S, Cunningham D. Toscani M, Nguyen J, Lim J, Ding Y, Vigdor S, Nahass RG, Ann Pharmacotherapy Annals of Pharmacotherapy, 1/1/2015
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 and Treatment-Experienced Cirrhotic Patients with HCV Genotype 2
Massetto B,Nahass RG, et al, Gastro, 1/1/2015
Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial
Everson GT, Towner WJ, David MN, Wyles D, Nahass RG, et al, Annals Int Med, 1/1/2015
Cefoxitin plasma and subcutaneous adipose tissue concentration in patients undergoing sleeve gastrectomy
Nahass RG, Clinical Therapeutics, 1/1/2015
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir(MK-8742) with or without ribavirin in patients with hepatitis C vir...
Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, et al, Lancet, 1/1/2014
Do clinical trials fit in private practice?
Nahass RG, Open Forum Infect Dis, 1/1/2014
Ledispavir plus GS-9451 and PegIFN/RBV with high SVR12 rates in genotype 1 hepatitis C infecton
Marcellin P, Manns MP, Janczewska E, Muir AJ, Wu X, Trenkle D, Pang P, Kanawar B, Dvory-Sobol H, Subramanian M, McHutchison J, Nahass RG, Gordon SC, Jacobson IM, NEJM, 1/1/2014
Infectious disease specialty intervention is associated with decreased mortality and lower healthcare costs
Schmitt S, McQuillen D, Nahass RG, et al, Clin Infect Dis, 1/1/2013
Electronic health record technology
Nahass TA, Nahass RG, JAMA, 1/1/2012
Hepatitis C screening: Summary of recommendations from the clinical decision tool
Boldt MD, Brill JV, Davis GL, Gordon SC, Kim AY, Kosinski LR, Levy AG, Nahass RG, Allen JI, Gastroenterology, 1/1/2012
Using active microbiologic surveillance and enhanced infection control measures to control an outbreak of health care-associated extended-spectrum beta-lactamase-produ...
Langer AJ, Lafaro P, Genese CA, McDonough P, Nahass R, Robertson C, Am J Inf C, 1/1/2009
The value of infectious diseases specialists: non – patient care activities
McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, et al, CID, 1/1/2008
Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline
S.L. Pett A1, H. Wand A1, M.G. Law A1,et al and the Community Programs for Clinical Research in AIDS (Nahass RG, member), HIV Clinical Trials, 1/1/2006
HIV – 1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors
Fitzgibbon JE, Dicola MB, Kiri S, Sha B, Pottage J, Nahass R, et al, Antiviral Therapy, 1/1/2001
Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections
Cheung T , Jayaweera D, Pearce, P Benson, Nahass R, Nusrat R, et al, Int J STD AIDS, 1/1/2000
A randomized trial of daily and thrice-weekly trimethoprim- Sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infec...
El-Sadr WM, Luskin-Hawk R, McCabe Yurik T, Walker J, et al and the Community Programs for Clinical Research in AIDS (Nahass RG, member), Clin Infect Dis, 1/1/1999
The Lyme disease controversy: Letter to the Editor
Nahass RG, Herman DJ, Hirsh EJ, Arch Intern Med, 1/1/1997
Vertebral osteomyelitis due to roseomonas: the first case and a review of the evaluation of vertebral osteomyelitis
Nahass RG, Wisneski R, Herman D, Hirsh E, Goldblatt K, Clin Infect Dis, 1/1/1995
Join now to see all

Abstracts/Posters

High efficacy of sofosbuvir/velpatasvir plus gs-9857 for 12 weeks in treatment-experienced genotype 1-6 hcv-infected patients, including those previously treated with ...
Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, Jacobson I, Tran T, Nahass RG, EASL, Barcelona, Spain, 1/1/2016
C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
Dore GJ, Altice F, Litwin AH, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, et al, EASL, Barcelona, Spain, 1/1/2016
High efficacy of grazoprevir/elbasvir among HCV GT1, GT4, or GT6 infected patients with HIV Co Infection
Nelson M, Rockstroh J, Mallolas J, Katlama C, Nahass RG, et al, ID Week, San Diego, CA, 1/1/2015
C-EDGE CO-STAR: Adherence and Drug use in HCV-Infected Persons who Inject Drugs (PWID) on Opioid Agonist Therapy (OAT) receiving Grazoprevir + Elbasvir (GZR/EBR) fixed...
Nahass RG, INHSU, 1/1/2015
Hepatitis C Virus (HCV) In Young Suburban Heroin Users In New Jersey; Part Of The Second Wave Of Hepatitis C
Nahass RG, et al, ID Week, San Diego, CA, 1/1/2015
Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in the treatment naive, noncirrhotic HCV genotype 3 infected patients
Gane E, Nahass RG, Luketic V, Hwang P, Robertson M, et al, EASL, Vienna, Austria, 1/1/2015
Implications of baseline HCV RNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-Week Treatement Outcomes
Brown RS, Puoti M, Cooper C, Wyles DL, Sepe TE, Nahass RG, et al, EASL, Vienna, Austria, 1/1/2015
A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (smv) plus sofosbuvir (sof) in treatment-naïve and -experie...
Kwo P, Gitlin N, Nahass RG, et al, EASL, Vienna, Austria, 1/1/2015
Sofosbuvir + PEGInterferon/Ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experineced cirrhotic ...
Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, et al, EASL, Vienna, Austria, 1/1/2015
Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genoty...
Sulkowski MS, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, 65th Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 1/1/2014
On treatment viral response of MK-5172/MK-8742 + RBV for 12 weeks in HCV/HIV Co- Infected Patient
Sulkowski M, Mallolas J, Pol S, Bouliere M, Gerstoft, Shibolet O, Nahass R, et al, Croi, 1/1/2014
Safety and Efficacy of Treatment with the Interferon-free, Ribavirin-free combination of Sofosbuvir+GS-5816 for 12 Weeks in Treatment Naïve Patients with Genotype 1-6 ...
Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass RG, McNally J, Bainard DM et al, EASL, London, UK, 1/1/2014
EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY
Sulkowski M, Mallolas J, Pol S, Bouliere M, Gerstoft, Shibolet O, Nahass R, et al, EASL, London, UK, 1/1/2014
Switch from NNRTI plus TVD to STB Maintains HIV Suppression and is Well- Tolerated
Markowitz M, Nahass RG, et al, American Conference for Treatment of HIV, Denver, CO, 1/1/2014
Innovations in Care to Provide Value in Healthcare Deliver Through Out-Patient Infusion Therapy
Heinemann D, Nahass RG, Manno A, Association for Vascular Access, National Harbor, MD, 1/1/2014
Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients, by Baseline Demographics
Nahass RG, Vierling JM, ID Week, Philadelphia, PA, 1/1/2014
Daclatasvir in combination with asunaprevir and BMS-791325 for prior null responders with chronic HCV genotype 1 infection
Gregory Everson G,Sims K,Thuluvath P,Schwartz H,Hassanein T,Lawitz E,Webster L,Bräu N,Desta T,Galati J,Ghalib R,Gitlin N,Han S,Hinestrosa F, Rodriguez-Torres M, Nahass..., 65th Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 1/1/2014
Demonstrating Value For Antibiotic Stewardship Program (ASP) Through Cost Saving, Improved Antimicrobial Resistance Patterns And Stable Clinical Outcomes In A Communit...
Nahass RG, Segal R, McDonnough P, Bollwage M, Brunetti L, IDSA, San Francisco, CA, 1/1/2013
Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data
Keyur Patel, Stuart C. Gordon, Aasim M. Sheikh, Ziad Younes, Julie Ma, John McNally, Diana M. Brainard, William T. Symonds, John G. McHutchison, Nahass RG, Eric M. Yos..., 64th Meeting of the Anerican Association for the Study of Liver Diseases, Washington, DC, 1/1/2013
High safety and efficacy of all oral combination regimen, MK 5172/MK 8742 +/- RBV for 12 weeks in HCV infected patients the C Worthy study
Lawitz E, Vierling J, Murillo A, Kugelmas M, Gerstoft J, Winkle P, Balart L, Christensen P, Ghalib R, Nahass RG, Shaughnessy M, Sun X, Hwang P, Wahl J, Robertson M, H..., 64th Meeting of the Anerican Association for the Study of Liver Diseases, Washington, DC, 1/1/2013
Effectiveness of a pharmacist managed vancomycin dosing protocol in achieving therapeutic levels in a Community Medical Center
Patel S, Segal R, Brunetti L,Kalabalik J, Nahass RG, IDSA, San Francisco, CA, 1/1/2013
Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data
K Patel, S Gordon, A Sheikh, Z Younes, J Ma, J McNally, DM Brainard, WT Symonds, JG McHutchison, R Nahass, EM Yoshida, H Reesink, D Nelson, AASLD, Washington, DC, 1/1/2013
High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study
Nahass RG, AASLD, Washington, DC, 1/1/2013
A Pseudo-epidemic of Tuberculosis Conversions Using Quantiferon Tb Gold In-tube (qft-git) for Testing High Risk Employees
Nahass RG, Pittarelli L, Lafaro P, McDonough P, ASM, Denver, CO, 1/1/2013
The Greying of an Epidemic: A Descriptive Study of HIV in Patients over 70 Years of Age
Nahass TA, Pittarelli L, McManus E, Nahass RG, ASM, Denver, CO, 1/1/2013
Join now to see all

Lectures

Hepatitits C in Clinical Practice
San Diego, CA - 1/1/2015
HIV/HCV Coinfection
1/1/2015
Infectious Disease Physicians and the Future of Healthcare
1/1/2015
Pre Exposure Prophylaxis
1/1/2014
Hepatitis C Update
1/1/2014
Hepatitis C in Clinical Practice
Philadelphia, PA - 1/1/2014
Innovations in Infectious Diseases Practice
1/1/2014
Infectious Diseases Strategies To Limit Hospitalization, Reduce Risk And Add Value
1/1/2014
Blood Borne Pathogen Risk Reduction
1/1/2014
ACO and the ID Clinician
1/1/2013
Hepatitis C Updat
1/1/2013
Hepatitis C and B: An Update
1/1/2013
Accountable Care and the ID Physician
1/1/2012
Numerous community presentations on Hepatitis C
1/1/2011
Health Care Reform
1/1/2011
Payment Reform - Physician Models
1/1/2011
A Day In the Life
Phoenix, AZ - 1/1/2010
Perinatal HIV
Phoenix, AZ - 1/1/2010
Metabolic Abnormalities of HIV
Phoenix, AZ - 1/1/2010
Blood Borne Pathogen
1/1/2009
HIV Update
1/1/2009
H1N1
1/1/2009
Infection Prevention Course
1/1/2009
Herpes Simplex Treatment and Mangement
1/1/2009
Hepatitis B
1/1/2009
Join now to see all

Press Mentions

ID Care President Dr. Ronald Nahass Voted ROI-NJ 2021 Healthcare InfluencerOctober 27th, 2021
Partner with N.J.’s Leading Infectious Disease SpecialistsApril 7th, 2021
NJ Now Has Nation's Highest Rate of New COVID Cases. Will Expected Vaccine Windfall Help?March 19th, 2021
Join now to see all

Professional Memberships

Infectious Disease Society of America - IDSA
Fellow
American College of Physician Executives - ACPE
Member
American College of Physicians - ACP
Fellow